ARCliDS: A Clinical Decision Support System for AI-assisted Decision-Making in Response-Adaptive Radiotherapy
Authors: Niraula Dipesh , Sun Wenbo , Jin Jionghua (Judy) , Dinov Ivo D. , Cuneo Kyle , Jamaluddin Jamalina , Matuszak Martha M. , Luo Yi , Lawrence Theodore S. , Jolly Shruti , Haken Randall K. Ten , Naqa Issam El 
Published: September 2022

Background

Involvement of many variables, uncertainty in treatment response, and inter-patient heterogeneity challenge objective decision-making in dynamic treatment regime (DTR) in oncology. Advanced machine learning analytics in conjunction with information-rich dense multi-omics data have the ability to overcome such challenges. We have developed a comprehensive artificial intelligence (AI)-based optimal decision-making framework for assisting oncologists in DTR. In this work, we demonstrate the proposed framework to Knowledge Based Response-Adaptive Radiotherapy (KBR-ART) applications by developing an interactive software tool entitled Adaptive Radiotherapy Clinical Decision Support (ARCliDS).

Methods

ARCliDS is composed of two main components: Artificial RT Environment (ARTE) and Optimal Decision Maker (ODM). ARTE is designed as a Markov decision process and modeled via supervised learning. Given a patient’s pre- and during-treatment information, ARTE can estimate treatment outcomes for a selected daily dosage value (radiation fraction size). ODM is formulated using reinforcement learning and is trained on ARTE. ODM can recommend optimal daily dosage adjustments to maximize the tumor local control probability and minimize the side effects. Graph Neural Network (GNN) is applied to exploit the inter-feature relationships for improved modeling performance and a novel double GNN architecture is designed to avoid unphysical treatment response. Datasets of size 117 and 292 were available from two clinical trials on adaptive RT in non-small cell lung cancer (NSCLC) patients and adaptive stereotactic body RT (SBRT) in hepatocellular carcinoma (HCC) patients, respectively. For training and validation, dense data with 297 features were available for 67 NSCLC patients and 110 features for 71 HCC patients. To increase the sample size for ODM training, we applied Generative Adversarial Network to generate 10,000 synthetic patients. The ODM was trained on the synthetic patients and validated on the original dataset.

Results

Double GNN architecture was able to correct the unphysical dose-response trend and improve ARCliDS recommendation. The average root mean squared difference (RMSD) between ARCliDS recommendation and reported clinical decisions using double GNNs were 0.61 ± 0.03 Gy/frac (mean±sem) for adaptive RT in NSCLC patients and 2.96 ± 0.42 Gy/frac for adaptive SBRT HCC compared to the single GNN’s RMSDs of 0.97 ± 0.12 Gy/frac and 4.75 ± 0.16 Gy/frac, respectively. Overall, For NSCLC and HCC, ARCliDS with double GNNs was able to reproduce 36% and 50% of the good clinical decisions (local control and no side effects) and improve 74% and 30% of the bad clinical decisions, respectively.

Conclusion

ARCliDS is the first web-based software dedicated to assist KBR-ART with multi-omics data. ARCliDS can learn from the reported clinical decisions and facilitate AI-assisted clinical decision-making for improving the outcomes in DTR.